Several brokerages have updated their recommendations and price targets on shares of Pliant Therapeutics (NASDAQ: PLRX) in the last few weeks: 5/15/2024 – Pliant Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock. 5/7/2024 – Pliant Therapeutics had its price target lowered by […]